Seagen: Long-Term Results from TUKYSA® Trial in HER2-Positive Breast Cancer at ASCO

 Updated Analysis Shows Median Overall Survival for TUKYSA Arm Extended to Two Years, with Benefit Maintained Across All Prespecified Patient Subgroups in HER2CLIMB Trial -

- Results Further Support TUKYSA as Well-Tolerated Treatment Option That Improves Survival in Patients with Previously Treated Metastatic HER2-Positive Breast Cancer With and Without Brain Metastases -

https://www.businesswire.com/news/home/20210603005326/en/Seagen-Announces-Long-Term-Results-from-TUKYSA%C2%AE-tucatinib-Pivotal-Trial-in-Patients-with-HER2-Positive-Breast-Cancer-During-the-Virtual-Scientific-Program-of-the-2021-ASCO-Annual-Meeting